Given the tendency towards adjuvant therapy in high-risk renal cell carcinomas and the corresponding need for risk assessment in these tumors, AR might deserve further evaluation as a potential clinically useful prognostic marker in these tumors. The gene discussed is AR; the disease is hereditary clear cell renal cell carcinoma.